Twin Tree Management LP Sells 29,820 Shares of Royalty Pharma plc (NASDAQ:RPRX)

Twin Tree Management LP lowered its position in shares of Royalty Pharma plc (NASDAQ:RPRX) by 39.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 45,431 shares of the biopharmaceutical company’s stock after selling 29,820 shares during the period. Twin Tree Management LP’s holdings in Royalty Pharma were worth $1,159,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Brooklyn Investment Group increased its position in shares of Royalty Pharma by 1,006.9% during the fourth quarter. Brooklyn Investment Group now owns 963 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 876 shares in the last quarter. Allworth Financial LP increased its position in shares of Royalty Pharma by 417.6% during the fourth quarter. Allworth Financial LP now owns 1,087 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 877 shares in the last quarter. Riverview Trust Co increased its position in shares of Royalty Pharma by 3,953.3% during the fourth quarter. Riverview Trust Co now owns 1,216 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 1,186 shares in the last quarter. Fifth Third Bancorp increased its position in shares of Royalty Pharma by 187.1% during the fourth quarter. Fifth Third Bancorp now owns 1,530 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 997 shares in the last quarter. Finally, Rakuten Securities Inc. increased its position in shares of Royalty Pharma by 160.5% during the fourth quarter. Rakuten Securities Inc. now owns 1,628 shares of the biopharmaceutical company’s stock valued at $42,000 after acquiring an additional 1,003 shares in the last quarter. Institutional investors own 54.35% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, TD Cowen raised shares of Royalty Pharma to a “strong-buy” rating in a research report on Tuesday, December 24th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Royalty Pharma has a consensus rating of “Buy” and a consensus target price of $41.60.

Royalty Pharma Trading Up 1.2 %

Shares of RPRX stock opened at $33.41 on Wednesday. Royalty Pharma plc has a 12-month low of $24.05 and a 12-month high of $34.20. The company has a current ratio of 1.44, a quick ratio of 1.44 and a debt-to-equity ratio of 0.64. The firm’s 50 day moving average is $31.88 and its 200 day moving average is $28.62. The stock has a market capitalization of $19.26 billion, a P/E ratio of 23.04, a P/E/G ratio of 2.31 and a beta of 0.47.

Royalty Pharma (NASDAQ:RPRX) last issued its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. Research analysts expect that Royalty Pharma plc will post 4.49 earnings per share for the current year.

Royalty Pharma Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, March 10th. Stockholders of record on Friday, February 21st were paid a dividend of $0.22 per share. This represents a $0.88 annualized dividend and a dividend yield of 2.63%. The ex-dividend date of this dividend was Friday, February 21st. This is a boost from Royalty Pharma’s previous quarterly dividend of $0.21. Royalty Pharma’s dividend payout ratio (DPR) is currently 60.69%.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.